Board of Directors

Our Board of Directors has a broad range of expertise, including public company management, financial acumen and product development.

Daniel G. Welch

Chairman, Board of Directors

Mr. Welch has spent his career of 40 years in the business of developing medicines. From January 2015 to February 2018, he was an Executive Partner at Sofinnova Investments, a leading Bay Area biotech venture capital firm. Prior to joining Sofinnova Investments, he was Chairman, President and CEO of InterMune until its acquisition by Roche in October of 2014. Before InterMune, he was Chairman and CEO of Triangle Pharmaceuticals, which was acquired by Gilead in 2003. Prior to Triangle, he was President of Biopharmaceuticals at Elan Corporation where he was responsible for its worldwide pharmaceutical operations, R&D and diagnostics businesses. From 1987 to 2000, he served in various senior management roles at Sanofi, including General Manager, Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business.

Mr. Welch currently serves as Chairman of the Board of Ultragenyx Pharmaceuticals, Executive Chairman of Levo Therapeutics, Executive Chairman of InCarda, and Director of Seattle Genetics and Intercept Pharmaceuticals. He served as Chairman of the Board of AveXis Inc. until it was acquired by Novartis Pharmaceuticals in 2018, and as a Director at Hyperion Therapeutics until it was acquired by Horizon Pharma in 2015. Mr. Welch earned a B.A. from the University of Miami and an M.B.A. from the University of North Carolina.

Robert Bazemore

Board of Directors

Mr. Bazemore has served as President, Chief Executive Officer and Director of Epizyme since September 2015.. Prior to joining Epizyme, he served as Chief Operating Officer of Synageva, where he established the company’s global commercial and medical organization to support the first product launch and helped lead the broader transition to a sustainable commercial enterprise, through its acquisition in July 2015. With more than 25 years of experience across the life sciences industry, Mr. Bazemore held several senior leadership positions at Johnson & Johnson, including President of Janssen Biotech, where he led the successful launches of numerous products and indications, including the U.S. launches of the oncology therapies ZYTIGA® and IMBRUVICA®, and guided the company’s worldwide immunology portfolio strategy. Prior to Johnson & Johnson, he worked at Merck & Co., Inc. for 11 years where he held roles of increasing responsibility, including the launch of SINGULAIR® in the U.S. He is a member of the Board of Directors of Ardelyx, Inc., and was a Board member of Neon Therapeutics. He earned a B.S. in biochemistry from the University of Georgia.

Kim D. Blickenstaff

Board of Directors
Mr. Blickenstaff is the Executive Chairman and Director of Tandem Diabetes Care, Inc., and previously served as the company’s President and Chief Executive Officer. Prior to that, he served as Chairman and Chief Executive Officer of Biosite Incorporated, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in 2007. Mr. Blickenstaff previously served as a Director of Medivation, Inc., until its acquisition by Pfizer in 2016, and a Director of DexCom, Inc., a provider of continuous glucose monitoring systems. Mr. Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He held various positions in finance, operations, research management, sales management, strategic planning and marketing with Baxter Travenol, National Health Laboratories and Hybritech Incorporated. He received a B.A. in political science from Loyola University Chicago and an M.B.A. from the Graduate School of Business, Loyola University Chicago.

Michelle Doig

Board of Directors
Ms. Doig is a Partner and Head of Corporate Development at Omega Funds, a leading investment firm. She has 20 years of experience advising life sciences companies on private placements, public equity financing and M&A transactions. Previously, she was Director of Corporate Finance at Third Rock Ventures, where she supported numerous portfolio companies. Prior to joining Third Rock, Ms. Doig was a Principal at Abingworth in London and Boston. She was also a life sciences investment banker with Lehman Brothers International in London, JP Morgan/H&Q in New York, and Morgan Stanley in Toronto and New York. Ms. Doig has executed more than 50 equity and convertible transactions and numerous IPOs, private placements and M&A transactions for companies, including Gilead, Global Blood Therapeutics (GBT), Illumina, MedImmune, Millennium, MyoKardia, Replimune and Sepracor. She graduated with an Honor’s degree in business administration from the Richard Ivey School of Business at the University of Western Ontario in London.
Ms. Doig will remain on the Board during a transition to be completed by June 1, 2021.

Kathryn Falberg

Board of Directors
Ms. Falberg currently serves as a member of the Board and Chair of the Audit Committee for several companies in the life sciences and technology industries, including Arcus Biosciences, UroGen Pharma, Tricida and The Trade Desk. Throughout her career, she has held several Chief Financial Officer roles in the biotechnology and technology industries, including for Applied Magnetics, Amgen and, most recently, Jazz Pharmaceuticals. Previously, Ms. Falberg served on the Board of Medivation until its acquisition by Pfizer, as well as other Boards including Aimmune Therapeutics, Halozyme Therapeutics, BioMarin Pharmaceutical and Human Genome Sciences. Ms. Falberg received a B.A. in economics and an M.B.A. from the University of California, Los Angeles.

David Hung, M.D.

Board of Directors

Dr. Hung founded Nuvation Bio in 2018 and serves as President and Chief Executive Officer and member of the Board of Directors. Dr. Hung founded Medivation, Inc., in 2003, raising a total of $440 million in public offerings over the life of the company to reach a market cap of more than $14 billion, providing investors with a return on investment of 21,000%. In 2016, Medivation was sold to Pfizer for $14.3 billion in an all-cash deal, one of the largest biopharma sales ever by a founding Chief Executive Officer. For his role in creating Medivation, Dr. Hung was named the Life Sciences category winner and Overall U.S. winner across all categories of the 2014 Ernst & Young Entrepreneur of the Year Award. Dr. Hung identified, in-licensed and led bench-to-bedside development of enzalutamide (XTANDI®) for advanced prostate cancer. At Medivation, XTANDI was taken from first in vitro laboratory experiment to FDA approval in seven years, one of the fastest development timelines in pharmaceutical history. XTANDI, approved in 60+ countries, reached blockbuster drug status, exceeding $2 billion in global annual sales in 2015. At Medivation, Dr. Hung identified, in-licensed and developed talazoparib, a potentially best-in-class PARP inhibitor, which was approved by the FDA in October 2018, and the immune-oncology agent, pidilizumab, which demonstrated robust effects in Phase 2 studies and is now a promising Phase 3-ready asset.

Between Medivation and founding Nuvation Bio, Dr. Hung served for 10 months as Chief Executive Officer at Axovant Sciences before tendering his resignation. Prior to founding Medivation, he served as President and Chief Executive Officer of ProDuct Health, Inc., a venture-backed startup medical device company founded in 1998 that developed, manufactured and commercialized a breast microcatheter – that he invented – for breast cancer risk assessment. ProDuct Health was acquired in 2001 for $168 million by Cytyc Corporation.

Dr. Hung received an A.B. summa cum laude in biology from Harvard College and an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine. He completed simultaneous clinical fellowships in hematology, oncology and transfusion medicine as well as two basic science research fellowships in molecular biology at the University of California, San Francisco, School of Medicine.

Oleg Nodelman

Board of Directors

Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With nearly twenty years of experience in biotech investing, Mr.

Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to the biotechnology sector. He currently serves as a Board Member for Prothena (NASDAQ: PRTA), a clinical-stage neuroscience company focused on the discovery and development of novel therapies. Mr. Nodelman is also the CEO and Chairman of Panacea Acquisition Corp (NYSE: PANA). Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University. (Mr. Nodelman will become a director upon completion of the pending merger between Nuvation Bio and Panacea Acquisition Corp.)

W. Anthony Vernon

Board of Directors

Mr. Vernon previously served as Chief Executive Officer of Kraft Foods Group, Inc., from 2012 until December 2014, and as President, Kraft Foods North America from 2009 to 2012. He also served as a senior advisors to the Board of Directors of Kraft Foods Group, Inc. until May 2015. Prior to joining Kraft, he was the healthcare industry partner of Ripplewood Holdings LLC, a private equity firm. Mr. Vernon spent 23 years at Johnson & Johnson where he ran independent business units and led several successful consumer brands. He currently serves as a Director on the Boards of Intersect ENT, Inc., NovoCure Limited, McCormick and Co., and on the Global Advisory Board of Northwestern University’s Kellogg School of Management. He previously served as a Director of Medivation, Inc., until its acquisition by Pfizer in 2016.